Table 1.
Clinicopathologic Characteristics of Patients with Pancreatic Cancer.
| Variable | n = 116 |
|---|---|
| Age, years (median ± SD) | 64.0 ± 10.4 |
| Gender | |
| Male | 67 (57.8) |
| Female | 49 (42.2) |
| BMI (median ± SD) | 22.1 ± 3.1 |
| Performance status (ECOG) | |
| 0 | 76 (65.5) |
| 1 | 36 (31.0) |
| 2 | 3 (2.6) |
| 3 | 1 (0.9) |
| CEA (ng/mL) (median ± SD) | 2.8 ± 34.3 (13 missing) |
| CA19-9 (U/mL) (median ± SD) | 393.0 ± 27295.3 |
| Smoking, n (%) | |
| Never | 78 (67.2) |
| Former | 22 (19.0) |
| Current smoker | 16 (13.8) |
| Treatment, n (%) | |
| Operation | |
| No | 103 (88.8%) |
| operation with curative intention | 13 (11.2%) |
| Chemotherapy | |
| No | 24 (20.7%) |
| Yes | 92 (79.3%) |
| Tumor mass size (cm) (median ± SD) | 4.0 ± 1.6 |
| Tumor location, n (%) | |
| Head | 49 (42.2) |
| Body | 41 (35.4) |
| Tail | 26 (22.4) |
| Stage (AJCC 8th edition), n (%) | |
| IA/B | 1 (0.9) |
| IIA | 6 (5.2) |
| IIB | 8 (6.9) |
| III | 26 (22.4) |
| IV | 75 (64.6) |
| Metastasis, n (%) | |
| None | 41 (35.3) |
| Liver | 45 (38.8) |
| Other sites except liver | 30 (25.9) |
SD, standard deviation; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; AJCC, The American Joint Committee on Cancer.